Related Experiment Video
Updated: Oct 7, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
A Non-Endoscopic Dynamic Nomogram for Atrophic Gastritis Risk Stratification Based on Serum Indicators and Clinical
1Department of Endoscopy Center, Shaoxing Second Hospital, Shaoxing, Zhejiang, People's Republic of China.
Background:
Atrophic gastritis (AG) is a key precancerous lesion in gastric carcinogenesis, underscoring the need for non-endoscopic screening tools to improve early detection. This study aimed to develop a predictive model for AG based on serum indicators and clinical factors.
Methods:
This single-center retrospective study enrolled 520 patients who underwent gastroscopy with biopsy at Shaoxing Second Hospital between January 2023 and December 2025. AG severity was classified via the Kimura-Takemoto system (no/mild: C0-C1, n=349; moderate/severe: C2-C3 and O-type, n=171). Multivariate analysis was performed to identify independent predictors. The performance of the resulting predictive model was evaluated, and decision curve analysis was used to evaluate the clinical utility across a range of threshold probabilities. An interactive dynamic nomogram was created for real-time risk calculation.
Results:
Multivariate analysis identified four independent predictors of moderate/severe AG: older age (OR = 1.082, P < 0.001), elevated neutrophil count (NE) (OR = 2.036, P = 0.043), decreased fibrinogen (FIB) (OR = 0.56, P < 0.001), and elevated carcinoembryonic antigen (CEA) (OR = 1.171, P = 0.011). The predictive model demonstrated good discrimination in the development cohort (AUC = 0.780) and was further evaluated in an independent 94-patient inter-campus cohort (AUC = 0.705), confirming its discriminatory ability within the same hospital system.
Conclusion:
This non-endoscopic model incorporating age, NE, FIB, and CEA provides a practical tool for AG risk stratification, As a single-center retrospective model, it requires further multi-center prospective validation before clinical implementation; nevertheless, it may help guide endoscopic surveillance decisions and contribute to the early prevention of gastric cancer.
Related Concept Videos
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Gastritis-I: Introduction and Types
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
Gastritis II: Pathophysiology
Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to: